NAUT Company Profile and Key Details

NAUT has shown sold momentum, gaining 3.02% over the past week and 111.34% over the past quarter, though year-to-date performance is up 5.13%. Short-term trend indicators are bearishly aligned (SMA20 3.29%, SMA50 13.32%, SMA200 85.07%). The stock’s 14-day RSI is 51.62 (neutral), while the ATR of 0.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.43% below its high and over 290.32% above its low. Average 10-day trading volume of 243.21 thousand shares is below the 3-month average of 307.78 thousand, indicating normal recent market interest.

Nautilus Biotechnology, Inc. has 126.31 million shares outstanding. The public float is 46.09 million shares, elevated short interest at 0.70% of float. This equals 344.07 thousand shares. The short ratio is 1.81 days. Institutional investors hold 74.65% of the float. Insiders own 33.47%. Mallick Parag holds 20.49 million shares, Patel Sujal M has 10.37 million shares and PERCEPTIVE ADVISORS LLC has 9.11 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Nautilus Biotechnology, Inc. generated EPS of -$0.50 over the past year. Five-year average earnings growth is -4.55%. Wall Street analysts project EPS growth of 5.67% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.14. Next year's EPS is expected at -$30.49. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $4.00. The high target offers 49.25% upside. The low target suggests 49.25% downside. The mean target is $4.00. This offers 49.25% upside. Nautilus Biotechnology, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended April 28, 2026, missed forecasts by -17.24%. The prior quarter beat by -21.43%. Over the last six quarters, Apple has recorded several small beats. These include -7.14% in April 29, 2025.

Nautilus Biotechnology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.14. This means the shares are trading below this model’s fair value.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) closed at $2.68 USD, losing -$0.20 (-6.94%) from the previous close of $2.88. The stock is currently mid-range between its 52-week high and low $0.62 and $4.31. With a market capitalization of about $340.57 million, Nautilus Biotechnology, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.75). Key stats such as the average daily volume over the past year has been around 309.31 thousand shares, in line with its 52-week average. Headquartered in Seattle, WA, Nautilus Biotechnology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sujal Patel, the company employs approximately 134 people and listed since August 07, 2020. Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) shares are flat 5.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Nautilus Biotechnology, Inc. trading at a premium to the broader market with a P/E of -5.99. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.47, suggesting 141.42% upside. Our AI forecast model points to short-term weakness (-0.37% over two weeks), a medium-term rise (262.31% over three months), and a longer-term gain (561.94% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Nautilus Biotechnology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.37%, with price expected at $2.67 by May 22, 2026, within a range of $2.18 to $3.14 3-Month Outlook: Projected rise of 262.31%, reaching $9.71 by August 06, 2026, with a range of $9.67 to $9.82. 1-Year Outlook: Projected gain of 561.94%, with price at $17.74 by May 07, 2027, within a range of $18.42 to $18.65.

Nautilus Biotechnology, Inc. trades at a P/E ratio of -5.99, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.37 suggesting the stock is closer to book value. The P/FCF stands at -6.67, also above market averages.